American Brachytherapy Society
24th Annual Meeting  ▶ May 8–10, 2003
Waldorf–Astoria Hotel
New York, New York

Jointly Sponsored by the American College of Radiology
Learning Objectives for 2003 Annual Meeting

To ensure a comprehensive understanding of the expanding role of imaging within the practice of brachytherapy. This will be accomplished through the exploration of advances in treatment technique and dosimetric evaluation as well as treatment outcome in gynecologic, breast, prostate and endovascular brachytherapy.

To increase the understanding of all aspects of brachytherapy application, including indications for use, technical considerations, quality assurance programs and outcome evaluations.

CME Statement for 2003 Annual Meeting

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American College of Radiology and the American Brachytherapy Society (ABS). The American College of Radiology is accredited by the ACCME to sponsor continuing medical education (CME) for physicians.

The American College of Radiology (ACR) designates the Annual Meeting for up to 22.25 hours of category 1 credit towards the AMA’s Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Conflict of Interest and Off-Label / Disclosure Statement

Presenters at this conference will disclose any conflict of interest or their intention to discuss off-label use, if applicable, in accordance with ACCME Standards and FDA requirements. Conflict of interest will be disclosed in print or in the final meeting materials.
ABS Past and Future Presidents

2004  Michael J. Zelefsky, MD
2003  Beth A. Erickson, MD
2002  Colin Orton, Ph.D.
2001  David Beyer, MD
2000  James Fontanesi
1999  Subir Nag, MD
1998  Kent Wallner, MD
1996-1997 Burton L. Speiser, MD
1995  Arthur T. Porter, MD
1994  John C. Blasko, MD
1993  Louis B. Harrison, MD
1992  Alvaro A. Martinez, MD
1991  Kenneth H. Luk, MD
1990  Peter A. Fleming, MD
1989  Dattatreyudu Nori, MD
1988  Karen K. Fu, MD
1987  Luis Delclos, MD
1986  Basil S. Hilaris, MD
1985  Don R. Goffinet, MD
1984  A.M. Nisar Syed, MD
1983  Thomas C. Gates, MD
1982  Ajmel A. Puthawala, MD
1981  Paul Y.M. Chan, MD
1980  Aaron G. Fingerhut, MD
1979  David L. Neblett, MS
1978  Harvey S. Frey, MD, Ph.D.

Thursday Night President’s Reception to Honor ABS Past Presidents

Everyone is invited to attend the President’s Reception on Thursday night, where we will be honoring the past presidents of the ABS. We hope to see you there!
Wednesday, May 7th

11:00 am – 6:00 pm
Exhibitor set-up / registration

12:00 – 6:00 pm
Registration

Thursday, May 8th

6:30 – 9:00 am
Exhibitor Set-up / registration

7:00 am – 5:00 pm
Registration

7:00 – 7:30 am
Continental Breakfast

9:00 am – 5:00 pm
Commercial Exhibits

7:30 – 8:30 am
GYNECOLOGIC BRACHYTHERAPY REFRESHER COURSE:

*Kaled Alektiar, MD and Bill Small, MD: Endometrial Cancer: Indications, Techniques, & Results*

Gynecologic Brachytherapy: Chair, Beth A. Erickson, MD

8:30 – 10:15 am
Gynecologic Brachytherapy Panel – Moderator, Beth A. Erickson, MD

*Nina Mayr, MD:*
*Imaging for Gynecologic malignancies*

*Jeff Williamson, PhD:*
*Image registration in Image-guided brachytherapy*

*Richard Poetter, MD:*
*CT and MRI–based Brachytherapy for Cervical Carcinoma*

Remaining time:
*Discussion/Questions*

10:15 – 10:40 am
Refreshment break and exhibit time

10:40 – 11:30 am
Proffered Papers - Gynecology and Colorectal

*Moderator - Manjeet Chadha, MD*

10:40 – 10:50 am
Does Pretreatment Calculation of Bladder and Rectal Doses In HDR Vaginal Cuff Brachytherapy after Therapy?

*William Small, MD*

10:50 – 11:00 am
High Dose Rate (HDR) Brachytherapy and External Beam for Primary Cancer of the Vagina

*D. Jeffrey Demanes, MD*
Cancer of the Cervix: 5 Year Results with Interstitial and Intracavitary High Dose Rate (HDR) Brachytherapy and External Beam  
D. Jeffrey Demanes, MD

RESIDENT TRAVEL AWARD  
Outcomes for Stage III Cervical Cancer Treated with External-Beam Radiation Therapy and High-Dose Rate Brachytherapy  
Sameer R. Keole, MD

RESIDENT TRAVEL AWARD  
Treatment of T3 and T4 Anal Cancer with Combined Chemoradiation and Interstitial Ir-192 Implant  
Julie M. Hwang, MD

Presidential Address  
The Sculpted Pair—Beth A. Erickson, MD

Lunch – on your own

Resident’s Luncheon

Ullrich Henschke Lecture  
Louis B. Harrison, MD  
Beth Israel Medical Center  
New York, NY

Breast Brachytherapy: Chair, Douglas Arthur, MD

Breast Brachytherapy Panel—Moderator, Douglas Arthur, MD

Thomas Julian, MD:  Phase III protocol development
Robert Kuske, MD:  RTOG phase II trial update
Csaba Polgar, MD:  Hungarian trial phase II/III update
David Wazer, MD:  Observations on toxicity
Remaining time:  Discussion/Questions

Refreshment break and Exhibit Time

Proferred papers - Breast and Head & Neck  
Moderators – Martin Keisch, MD and David Donath, MD

Multiple Dwell Positions with the Mammosite[Reg] HDR Applicator  
Gene A. Cardarelli, MD
Amercian Brachytherapy Society 24th Annual Meeting
May 8–10, 2003 ▶ Waldorf–Astoria Hotel ▶ New York, New York

3:50 – 4:00 pm  
RESIDENT TRAVEL AWARD
CT-Guided Multi-Catheter Insertion Technique for Partial Breast Brachytherapy (PBB): Reliable Target Coverage and Dose Homogeneity
Laurie W. Cuttino, MD

4:00 – 4:10 pm
A Quantitative Methodology for Measuring Conformance Index of MammoSite Catheter Treatments
Mark J. Rivard, PhD

4:10 – 4:20 pm
Dosimetric Assessment of the Mammosite[Reg] RTS Radiation Therapy System
Dorin Todor, PhD

4:20 – 4:30 pm
High-Dose-Rate Intraoperative (HDR-IORT) Radiation for Head and Neck Cancer
Kenneth Hu, MD

4:30 – 5:30 pm
ABS Annual Debate - I
“Accelerated Partial Breast Irradiation is equivalent to standard whole breast irradiation”
Moderator – David Wazer, MD
Frank Vicini, MD - Pro
Abram Recht, MD - Con
Discussion/questions

6:00 – 8:00 pm
Welcoming President’s Reception

Friday, May 9th

7:00 am – 5:00 pm
Registration

9:00 am – 5:00 pm
Commercial Exhibits

7:00 – 7:30 am
Continental Breakfast

7:30 – 8:30 am
BREAST BRACHYTHERAPY REFRESHER COURSE
Douglas Arthur, MD - Essentials of Breast Brachytherapy – Multi-Cath and MammoSite
### Vascular Brachytherapy: Chair, Phillip Devlin, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 – 10:15 am</td>
<td>Vascular Brachytherapy Session</td>
</tr>
<tr>
<td>8:30 am</td>
<td><strong>Phillip Devlin, MD:</strong> Welcome and Introduction</td>
</tr>
<tr>
<td>8:35 am</td>
<td><strong>Louis Harrison, MD:</strong> Dosimetry for Vascular Brachytherapy: What’s New?</td>
</tr>
<tr>
<td>8:50 am</td>
<td>Evaluation of Overlap and Geographic Miss Associated with Manual Pullback Procedure for IVBT Robert Cormack, PhD</td>
</tr>
<tr>
<td>9:00 am</td>
<td><strong>Intravascular Brachytherapy Using [Sup]90[/Sup]Sr for Saphenous Vein Grafts Having Diameters Ranging from 2.0-5.0mm</strong> Mark J. Rivard, PhD, to be presented by John Mignano, MD</td>
</tr>
<tr>
<td>9:10 am</td>
<td><strong>Jay Ciezki, MD:</strong> Response and discussion</td>
</tr>
<tr>
<td>9:20 am</td>
<td><strong>Coronary Brachytherapy in the Era of Drug Eluting Stents</strong> Phillip Devlin, MD</td>
</tr>
<tr>
<td>9:35 am</td>
<td>Treatment Of Refractory In-Stent Restenosis With Intravascular Brachytherapy And Paclitaxel Coated Stents: Determination Of Efficacy Of Radiosensitization Using Finite Element Methods To Model Drug Uptake Anthony Abner, MD</td>
</tr>
<tr>
<td>9:45 am</td>
<td><strong>Colin Orton, PhD:</strong> Response and discussion</td>
</tr>
<tr>
<td>9:55 am</td>
<td>Vascular Brachytherapy for Peripheral Disease – An Update <strong>Prabhakar Tripuraneni, MD</strong></td>
</tr>
<tr>
<td>10:10 am</td>
<td>Panel: Response and discussion</td>
</tr>
<tr>
<td>10:15 am</td>
<td>Session End</td>
</tr>
<tr>
<td>10:15 – 10:45 am</td>
<td>Refreshment Break and Exhibit Time</td>
</tr>
<tr>
<td>10:45 – 11:15 am</td>
<td>Proffered papers – Physics <strong>Moderator – Colin Orton, PhD</strong></td>
</tr>
<tr>
<td>10:45 – 10:55 am</td>
<td><strong>Update Of AAPM Task Group No. 43 Report [Ndash] A Revised AAPM Protocol For Interstitial Brachytherapy Dose Calculations</strong> Mark J. Rivard, PhD</td>
</tr>
</tbody>
</table>
Dependence of Brachytherapy Dosimetry on the Uniformity of the Isotope Physical Distribution
Mark J. Rivard, PhD, to be presented by Mark J. Engler, PhD

Dose Rates from [sup]125[/sup]I and [sup]103[/sup]Pd Brachytherapy Sources in Realistic Media at Distances Up to 30 Cm
Mark J. Rivard, PhD, to be presented by Jody Morr, DO

History – Pioneers of Brachytherapy
Jesse Aronowicz, MD

Members Annual Business Meeting and Lunch

---

Proffered Papers - Prostate I

Contouring Consensus Results
W. Robert Lee, MD and Michael Zelefsky, MD

Proffered Papers - Prostate I

Moderators - W. Robert Lee, MD and Matthew Manning, MD

Impact of PSA Failure on Overall and Cancer Specific Survival Following Permanent Prostate Brachytherapy
David Beyer, MD

Searching for a Better Prostate Seed Implant: A New Rapid Strand After-Loading Technique
Humberto M. Fagundes, MD

Prostate Brachytherapy Seed Migration and Dosimetry: Analysis Of Potential Predictive Factors
Donald B. Fuller, MD

A Comparison of the Dosimetry of Seeds in Suture and Loose Seeds for Permanent Prostate Brachytherapy
Marshall Lieberfarb, MD

CT, MRI, and CT-MRI Image Fusion Assessment for Prostate I-125 Post Implant Dosimetry
Bashar M. Al-Qaisieh, MSc

MRI-CT Fusion to Assess Post Bt Prostate Volume and the Effects of Prolonged Edema on Dosimetry Following Transperineal Interstitial Permanent Prostate Brachytherapy (TIPPB)
Juanita M. Crook, MD
**RESIDENT TRAVEL AWARD**
Isodose Patterns In Patients With Inadequate Prostate Brachytherapy Coverage, And Its Application To Intraoperative Dosimetry Planning
Daniel R. Reed, DO

**2:55 – 3:25 pm**
Refreshment break and Exhibit Time

**3:25 – 4:15 pm**
**Proffered Papers - Prostate II**

Moderators - Michael Zelefsky, MD and Juanita Crook, MD

3:25 – 3:35 pm
Quantitative Impact of Intraoperative Planning on Dosimetric Values
Gary M. Kirsh, MD

3:35 – 3:45 pm
Intraoperative Preplanning Improve Implant Quality and Biochemical Disease-free Survival in Patients Treated with Permanent Prostate Brachytherapy
Ronald D. Ennis, MD

3:45 – 3:55 pm
**RESIDENT TRAVEL AWARD**
Are There Significant Advantages to Intraoperative Planning Compared to Preoperative Planning for Permanent Prostate Seed Implants?
Prem Raja, MD

3:55 – 4:05 pm
Comparison of Real-Time US Implantation of the Prostate Using a Look-Up Nomogram Versus US Assisted Implantation Using the Variseed Optimization Program: Improved Target Coverage with Reduced Urethral and Rectal Dose
Adam Raben, MD

4:05 – 4:15 pm
Correction for Dosimetric Changes Due to Prostate Deformation when Using Ultrasound Probe Stand
Young-Bin Cho, MD

4:15 – 5:30 pm
Salvage Brachytherapy – Imaging, Technique and Results

Moderator – **David Beyer, MD**
Bradley Prestidge, MD
Michael Hagan, MD

Remaining time: Discussion/Questions

6:30 – 9:30 pm
Gala Night Out
Sponsored by Varian Brachytherapy
Heartbeat Restaurant at W Hotel
Saturday, May 10th

7:00 – 9:00 am  Registration
9:00 am –12:15 pm  Commercial Exhibits
7:00 – 7:30 am  Continental Breakfast
7:30 – 8:30 am  **PROSTATE BRACHYTHERAPY REFRESHER COURSE**  
                 *John Sylvester, MD*: Prostate Brachytherapy
8:30 – 9:30 am  Proferred papers - Prostate III  
                 Moderators - Richard Stock, MD and Louis Potters, MD
8:30 – 8:40 am  **RESIDENT TRAVEL AWARD**  
                 The Role of Prophylactic Tamsulosin (Flomax[Reg]) in Patients Undergoing Prostate [Sup]125[/Sup]I Seed Implants for Prostate Carcinoma. Double Blind Randomized Study  
                 Mohamed A. Elshaikh, MD
8:40 – 8:50 am  **RESIDENT TRAVEL AWARD**  
                 Incontinence Associated with Transurethral Resection of the Prostate for Patients Treated with Permanent Prostate Brachytherapy  
                 Rajiv J. Patel, MD
8:50 – 9:00 am  Long-Term Urinary Quality of Life Following Permanent Prostate Brachytherapy  
                 Gregory S. Merrick, MD
9:00 – 9:10 am  A Prospective Study of Sexual Potency and Sexual Satisfaction in Men Undergoing Permanent Seed Brachytherapy for Carcinoma of the Prostate  
                 Gerald C. Morton, MD
9:10 – 9:20 am  Anterior Rectal Wall DVH after I-125 Permanent Prostate Implant:  
                 Can We Use it to Predict Rectal Toxicity?  
                 Mira Keyes, MD, FRCPC
9:20 – 9:30 am  **RESIDENT TRAVEL AWARD**  
                 Combined Radioactive Gold Seed Brachytherapy and Intensity-Modulated Radiation Therapy (IMRT) [Quot]Dose Painting[Quot] Via [Quot]Smart Boost[Quot] in the Treatment of Localized Prostate Cancer: Toxicity and Biochemical Control  
                 Michael D. Bastasch, MD
American Brachytherapy Society 24th Annual Meeting
May 8–10, 2003 ▶ Waldorf–Astoria Hotel ▶ New York, New York

9:30 – 10:00 am Refreshment break

10:00 – 11:05 am Progress in Ultrasound Imaging For Prostate Brachytherapy: Moving Towards Real Real-Time Dosimetry
Moderator – Anthony D'Amico, MD
Brian Davis, MD
Patrick McLaughlin, MD
Remaining time: Discussion / Questions

11:05 – 11:45 am Proffered papers - Prostate IV
Moderators - Kent Wallner, MD and Bradley Prestidge, MD

11:05 – 11:15 am Technical and Dosimetric Evaluation of Ct-Based Temporary HDR Interstitial Brachytherapy of the Prostate Gland
John K. Hayes, MD

11:15 – 11:25 am RESIDENT TRAVEL AWARD
A Prospective Observational Study of the Cytoreductive Efficacy of Goserehin and Bicalutamide Prior to Brachytherapy
Robert W. Laing, MRCP, FRCR

11:25 – 11:35 am Radioimmunoguided Transperineal Brachytherapy with or without External Beam Radiotherapy for Hormone-Naïve Patients with Prostate Adenocarcinoma
Rodney J. Ellis, MD

11:35 – 11:45 am MRSI-Directed Regional Salvage Brachytherapy of the Prostate Following Recurrence after External Beam Irradiation
Michael Hagan, MD, PhD

11:45 am – 12:30 pm ABS Annual Debate – II
“CT is adequate for postimplant quality assessment”
Moderator – W. Robert Lee, MD
Gregory Merrick, MD - Pro
Juanita Crook, MD - Con
Discussion/questions

12:15 pm Meeting adjourns

12:15 – 1:30 pm Exhibitor tear-down
### Meeting Space Key

<table>
<thead>
<tr>
<th>Day</th>
<th>Function</th>
<th>Room(s) / Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday</td>
<td>Commercial Exhibits</td>
<td>Empire, Hilton</td>
</tr>
<tr>
<td>Thursday</td>
<td>General Sessions</td>
<td>Starlight Roof</td>
</tr>
<tr>
<td>Thursday</td>
<td>Speaker Ready Room</td>
<td>Norse Suite</td>
</tr>
<tr>
<td>Thursday</td>
<td>Resident’s Luncheon</td>
<td>Morgan Suite</td>
</tr>
<tr>
<td>Thursday</td>
<td>President’s Reception</td>
<td>Louis XVI Suite</td>
</tr>
<tr>
<td>Thursday</td>
<td>Posters</td>
<td>Promenade Suites (lower level)</td>
</tr>
<tr>
<td>Friday</td>
<td>Commercial Exhibits</td>
<td>Empire, Hilton</td>
</tr>
<tr>
<td>Friday</td>
<td>General Sessions</td>
<td>Starlight Roof</td>
</tr>
<tr>
<td>Friday</td>
<td>Speaker Ready Room</td>
<td>Norse Suite</td>
</tr>
<tr>
<td>Friday</td>
<td>Annual Business Meeting and Member Lunch</td>
<td>Astor Salon</td>
</tr>
<tr>
<td>Friday</td>
<td>Posters</td>
<td>Promenade Suites (lower level)</td>
</tr>
<tr>
<td>Friday</td>
<td>Gala Event</td>
<td>Heartbeat Restaurant at the W Hotel</td>
</tr>
<tr>
<td></td>
<td></td>
<td>541 Lexington Avenue</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6:30 to 9:30 pm</td>
</tr>
<tr>
<td>Saturday</td>
<td>Commercial Exhibits</td>
<td>Empire, Hilton</td>
</tr>
<tr>
<td>Saturday</td>
<td>General Sessions</td>
<td>Starlight Roof</td>
</tr>
<tr>
<td>Saturday</td>
<td>Speaker Ready Room</td>
<td>Norse Suite</td>
</tr>
<tr>
<td>Saturday</td>
<td>Posters</td>
<td>Promenade Suites (lower level)</td>
</tr>
</tbody>
</table>
**Acknowledgment of Commercial Support**

The American Brachytherapy Society would like to acknowledge the support, through an unrestricted educational grant, of the following organizations:

- Amersham Health (Travel Grant Awards)
- Best Medical International (attendee tote bags; Ulrich Henschke Memorial Lecture)
- Theragenics Corporation (Resident’s Luncheon)
- Varian Brachytherapy (Gala Event)

**ABS 2003 Gala Event and Acknowledgment of Commercial Support**

*Sponsored by Varian Brachytherapy*

The ABS would like to acknowledge the support of the 2003 Gala Event by Varian Brachytherapy, through an unrestricted educational grant.

This year’s Gala Event will be held at the Heartbeat Restaurant in the W Hotel, located across the street from the Waldorf–Astoria Hotel (541 Lexington Avenue). Enjoy light food, drinks and music while networking and talking with fellow attendees, exhibitors and guests. This event is included in the registration fee for attendees and guests, however exhibitors are required to register separately at a fee of $150. Take the time to walk through this unique and upscale hotel; opened in 1998, the “W experience” began in New York and its success brought 12 more W hotels around the world over the next twelve months, including Sydney, Los Angeles, Seattle, Honolulu, New Orleans, San Diego and Chicago. Each hotel offers signature restaurant and bar areas. The W vision sees the hotel as a wonderful gathering place, much like the grand hotels of the early 1900s. Join your colleagues for this year’s Gala Event.
### American Brachytherapy Society
The Waldorf-Astoria  May 8–10, 2003

#### 2003 Annual Meeting Exhibitors

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
<th>Tabletop Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amersham Health</td>
<td>10, 11</td>
<td></td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Bard Urological Division</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Best Medical International &amp; Cordis</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>B-K Medical Systems, Inc.</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td>Capintec</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Computerized Medical Systems</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Draximage, Inc.</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Elsevier</td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>Guidant Corporation</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>IBT, Inc.</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Implant Sciences Corporation/MED-TEC</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Isoaid LLC</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>Kawasumi Laboratories America</td>
<td>17, 18</td>
<td></td>
</tr>
<tr>
<td>Mentor Corporation</td>
<td>7, 8</td>
<td></td>
</tr>
<tr>
<td>MICK Radio Nuclear Instruments</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Nucletron</td>
<td>23, 24, 25, 26</td>
<td></td>
</tr>
<tr>
<td>North American Scientific, Inc.</td>
<td>19, 20, 29, 30</td>
<td></td>
</tr>
<tr>
<td>Novoste Corporation</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Pro-Qura</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Proxima Therapeutics, Inc.</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>SourceTech Medicale</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Theragenics Corporation</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Varian Brachytherapy</td>
<td>4, 5, 6</td>
<td></td>
</tr>
<tr>
<td>World Wide Medical Technologies</td>
<td>1, 2</td>
<td></td>
</tr>
</tbody>
</table>
ABS Board of Directors
President: Beth A. Erickson, MD
Vice President: Michael J. Zelefsky, MD
Secretary: Frank A. Vicini, MD
Treasurer: Douglas W. Arthur, MD
Chairman: Colin G. Orton, PhD

Members-at-Large
Gary S. Gustafson, MD
W. Robert Lee, MD
Richard G. Stock, MD
Prabhakar Tripuraneni, MD

Annual Meeting Scientific Program Committee
Douglas W. Arthur, MD, Scientific Program Chair
Beth A. Erickson, MD
W. Robert Lee, MD
Phillip M. Devlin, MD

Annual Meeting Faculty
Anthony Abner, MD
Kaled Alektiar, MD
Jesse Aronowicz, MD
Douglas Arthur, MD
David Beyer, MD
Jay Ciezki, MD
Juanita Crook, MD
Anthony D’Amico, MD
Brian Davis, MD
Phillip Devlin, MD
Beth Erickson, MD
Michael Hagan, MD
Louis Harrison, MD
Tom Julian, MD
Robert Kuske, MD
W. Robert Lee, MD
Nina Mayr, MD
Robert Cormack, PhD
Patrick McLaughlin, MD
Gregory Merrick, MD
John Mignano, MD
Csaba Polgar, MD
Richard Poetter, MD
Bradley Prestidge, MD
Abram Recht, MD
Bill Small, MD
John Sylvester, MD
Prabhakar Tripuraneni, MD
Frank Vicini, MD
David Wazer, MD
Jeff Williamson, MD
Michael Zelefsky, MD
ABS Awards
Amersham Health Prostate Brachytherapy Fellowship Award Winners

Lisa Berle  
Tufts

Darren Little  
MD Anderson

Sean Cavanaugh  
UT San Antonio

Peter Swindle  
MSKCC

Maria Dulay-De Jesus  
Howard University

Robert Takamiza  
UCSF

Past Henschke Medal Recipients

1981 Basil Hilaris, MD  
Primary Irradiation on the Management of Cancer of the Breast

1981 A.M. Nisar Syed, MD  
Primary Irradiation on the Management of Cancer of the Breast

1982 Lowell Anderson, PhD

1984 Bernard Perquin, MD  
Account of French Fellows

1984 Eric Hall, DSc  
The Biological Basis of Endocurietherapy

1985 Samuel Hellman, MD  
Preservative Management of Breast Cancer

1986 Theodore L. Phillips, MD  
Neurobrachytherapy, State of the Art

1988 Charles A.F. Joslen, MD  
High Activity Source Afterloading in Gynecological Cancer and Its Future Prospects

1989 Professor Daniel Chassagre  
Results of Oral Cancer Brachytherapy

1989 J. Frank Wilson, MD  
Combined Modality Treatment with Brachytherapy

1990 Jack Fowler, DSc  
The Role of Radiation Biology in Brachytherapy

1991 Carlos Perez, MD, FACR  
A Historic Perspective and Challenges in Brachytherapy of the Uterine Cervix

1992 Willet Whitmore, MD  
The Memorial Sloan Kettering Experience with 125-I for Prostrate Cancer: 1970-1985

1993 Alain Gerbaulet, MD  
Brachytherapy for Pediatric Malignancies

1994 Ravinder Nath, PhD  
New Radionuclide Sources for Brachytherapy

1995 Colin Orton, PhD  
The Dose-Rate Effect in Brachytherapy: Friend or Foe?

1999 Luis Delclos, MD  
Irradiation for Malignant Tumors of the Vagina

2003 Louis B. Harrison, MD
Louis B. Harrison, M.D.

Louis B. Harrison, M.D. is Clinical Director of the Continuum Cancer Centers of New York. He is also Chairman of Radiation Oncology for Beth Israel Medical Center and St. Luke’s – Roosevelt Hospital Center, and Co-Director of the Institute for Head and Neck Cancer. He is an internationally recognized and extensively published expert in the areas of head and neck cancer, sarcomas and intraoperative brachytherapy. He has recently become involved in the study of anemia and its impact on oncologic outcomes. Before joining Beth Israel Medical Center in 1997, Dr. Harrison was Chief of the Brachytherapy Service and Leader of the Head and Neck Cancer Disease Management Team at Memorial Sloan-Kettering Cancer Center. He is Professor of Radiation Oncology at Albert Einstein College of Medicine.


Dr. Harrison received his bachelor’s degree from Duke University and earned his medical degree from the State University of New York Downstate Medical Center’s College of Medicine where he was a member of the Alpha Omega Alpha Honor Society. He did his internship at Mount Sinai Medical Center, and then completed a residency in therapeutic radiology at the Yale University School of Medicine.

Dr. Harrison has been a member of the American Brachytherapy Society since 1986. He became Chairman of the Scientific Program Committee in 1989, and was a member of the Board of Directors from 1991-1995 serving as Treasurer in 1991, Vice President in 1992, and President in 1993. He has continued to be very active in brachytherapy with special expertise in head and neck brachytherapy, intraoperative brachytherapy, and vascular brachytherapy. He has also published on the use of brachytherapy for soft tissue sarcomas, nasopharyngeal carcinomas, and vaginal cancers, as well as pancreatic tumors and liver metastases.

It is a pleasure to honor Dr. Louis Harrison with the 2003 Henschke Award.
2003 ABS Resident Travel Grant Award Recipients

Paper Presentations

Michael Bastasch, MD
*Combined Radioactive Gold Seed Brachytherapy and Intensity-Modulated Radiation Therapy (IMRT) [quot] Dose Painting [quot] Via [quot] Smart Boost [quot] in the Treatment of Localized Prostate Cancer: Toxicity and Biochemical Control*

Laurie W. Cuttino, MD
*CT-Guided Multi-Catheter Insertion Technique for Partial Breast Brachytherapy (PBB): Reliable Target Coverage and Dose Homogeneity*

Mohamed A. Elshaikh, MD
*The Role of Prophylactic Tamsulosin (Flomax [reg]) in Patients Undergoing Prostate [sup] 125 [/sup] I Seed Implants for Prostate Carcinoma. Double Blind Randomized Study.*

Julie M. Hwang, MD
*Treatment of T3 and T4 Anal Cancer with Combined Chemoradiation and Interstitial IR-192 Implant*

Sameer Keole, MD
*Outcomes for Stage III Cervical Cancer Treated with External-Beam Radiation Therapy and High-Dose Rate Brachytherapy*

Rajiv J. Patel, MD
*Incontinence Associated with Transurethral Resection of the Prostate for Patients Treated with Permanent Prostate Brachytherapy*

Prem Raja, MD
*Are There Significant Advantages to Intraoperative Planning Compared to Preoperative Planning for Permanent Prostate Seed Implants?*

Daniel R. Reed, DO
*Isodose Patterns in Patients with Inadequate Prostate Brachytherapy Coverage, and its Application to Intraoperative Dosimetry Planning*

Poster Presentations

Kelly D. DeWitt, MD
*Comparison of Anatomy-Based Inverse Planning Dose Optimization with Conventional Dose Prescription Methods for High-Dose-Rate Treatment of the Cervix*

S. Christopher Hoffelt, MD
*Epididymitis Following Prostate Brachytherapy*

Hiral K. Shah, MD
*3-D Treatment Planning Offers Improved Target Volume Delineation and Geometric Coverage for HDR Interstitial Accelerated Partial Breast Irradiation*

Neenad M. Shah, MD
*Initial Cosmesis and Toxicity with Mammosite Brachytherapy for Partial Breast Irradiation in Breast-Conserving Therapy for Women with Early-Stage Breast Cancer*

Sherif Yacoub, MD, PhD
*Vaginal Recurrences in Previously Irradiated Endometrial Cancer: Result of Salvage Interstitial Brachytherapy*
ABS Posters *(located in Promenade Suites)*

**Gynecology**

**P-39**

**VAGINAL RECURRENCES IN PREVIOUSLY IRRADIATED ENDOMETRIAL CANCER: RESULT OF SALVAGE INTERSTITIAL BRACHYTHERAPY**

Sherif Yacoub, MD, PHD,¹ Subir Nag, MD,¹ Larry J Copeland, MD,² Jeffrey M Fowler, MD.² ¹Radiation Oncology, Ohio State Univ, Columbus, OH; ²Division of Gynecologic Oncology, Ohio State Univ, Columbus, OH.

**P-41**

**A FREEHAND TRANSRECTAL ULTRASOUND GUIDED INTERSTITIAL IMPLANT TECHNIQUE WITH INVERSE PLANNING FOR GYNECOLOGIC MALIGNANCIES**

Christopher Biggs, MD, PhD,¹ Etienne Lesard, M.Sc.,¹ Arun Sharma, B.D.S.,M.Sc.,¹ Joycelyn Speight, MD, PhD,¹ Jean Pouliot, Ph.D.,¹ I-Chow Hsu, MD.¹ ¹Radiation Oncology, University of California San Francisco, San Francisco, CA.

**P-42**

**COMPARISON OF ANATOMY-BASED INVERSE PLANNING DOSE OPTIMIZATION WITH CONVENTIONAL DOSE PRESCRIPTION METHODS FOR HIGH-DOSE-RATE TREATMENT OF THE CERVIX**

Kelly D DeWitt, MD,¹ I Chow Joe Hsu, MD,¹ Vivian K Weinberg, PhD,² Etienne Lessard, MSc,¹ Jean Pouliot, PhD.¹ ¹Radiation Oncology, University of California, San Francisco, San Francisco, CA; ²Biostatistics Core, University of California, San Francisco, San Francisco, CA.

**P-43**

**DOSIMETRIC COMPARISON BETWEEN TWO INTRACA VITARY BRACHYTHERAPY FOR CANCER OF THE CERVIX: MANCHESTER SYSTEM VERSUS EDINBURGH SYSTEM**

Robert Y Kim, M.D., Jill F Caranto, R.T. (R)(T) C.M.D., Jun Duan, Ph.D. ¹Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL.

**P-44**

**CISPLATIN IN COMBINATION WITH FRACTIONATED HDR INTRACA VITARY BRACHYTHERAPY FOR PATIENTS WITH CANCER OF THE UTERINE CERVIX - A PILOT STUDY**

Travers J McLoughlin, M.D.,¹ Jaganmohan Poli, M.D.,¹ D Yi-Shin Kuo, M.D.,² Dattatreyudu Nori, M.D., F.A.C.R.¹ ¹Department of Radiation Oncology, New York Hospital Medical Center at Queens, Flushing, NY; ²Department of Ob/Gyn - Division of Gynecologic Oncology, New York Hospital Medical Center at Queens, Flushing, NY.

**Breast**

**P-45**

**INITIAL COSMESIS AND TOXICITY WITH MAMMOSITE BRACHYTHERAPY FOR PARTIAL-BREAST IRRADIATION IN BREAST-CONSERVING THERAPY FOR WOMEN WITH EARLY-STAGE BREAST CANCER**

Neenad M Shah, MD,¹,² Todd Tenenholz, MD, PhD,³ Thomas A DiPetrillo, MD,¹,² Douglas W Arthur, MD,³ Gene A Cardarelli, MSc, MPH,² Zhen Zheng, PhD,² Mark J Rivard, PhD,² Bruce A Bornstein, MD, MBA,¹ David E Wazer, MD.¹,² ¹Radiation Oncology, Tufts - New England Medical Center, Boston, MA; ²Radiation Oncology, Rhode Island Hospital, Providence, RI; ³Radiation Oncology, Medical College of Virginia of VCUHS, Richmond, VA.
P-46
3-D TREATMENT PLANNING OFFERS IMPROVED TARGET VOLUME DELINEATION AND GEOMETRIC COVERAGE FOR HDR INTERSTITIAL ACCELERATED PARTIAL BREAST IRRADIATION
Hiral K Shah, MD,1 Rakesh R Patel, MD,1 Rupak Das, PhD,1 Afshin Forouzannia, MD,1 Heath Odau, MS,1 Robert R Kuske, MD.1 1Department of Human Oncology, University of Wisconsin, Madison, WI.

P-49
BREAST CONSERVATION UTILIZING TEMPORARY 125 IODINE INTERSTITIAL BRACHYTHERAPY FOLLOWING LUMPECTOMY FOR ISOLATED IN-BREAST RECURRENCE
Mark G Trombetta, M.D.,1 Thomas B Julian, M.D.,2 Janna Z Andrews, M.D.,1 Mary Beth Malay, M.D.,2 Marcel M Szal, M.S.,1 E Day Werts, Ph.D.,1 David S Parda, M.D.1 1Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA; 2Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA; 1Department of Radiation Oncology, Wyoming Medical Center, Casper, WY.

Head and Neck

P-50
DOSE CALCULATION INACCURACY DUE TO SEED POSITION ERRORS IN EYE PLAQUES WITH IRREGULAR SOURCE PATTERN
Eugene P Lief, Ph.D.,1 J Keith De Wyngaert, Ph.D.,1 Bruce E Ellerin, M.D.,1 Silvia C Formenti, M.D.1 1Radiation Oncology, New York University Medical Center, New York, NY.

P-51
SALVAGE BRACHYTHERAPY FOR HEAD AND NECK CANCER: RETREATMENT IN PREVIOUSLY IRRADIATED AREA
V. Strnad, MD, Assoc.Prof.,1 M. Geiger, MD,1 M. Lotter, PhD,1 R. Sauer, MD, Prof.1 1Dept. of Radiation Oncology, University Erlangen-Nuremberg, Erlangen, Germany.

Intravascular

P-52
DOSE VARIABILITY ALONG A SEED STRAND DUE TO STRAND CURVATURE IN CORONARY INTRAVASCULAR BRACHYTHERAPY
Martin Bues, Ph.D., Edward J Holupka, Ph.D., Anthony L Abner, M.D. 1Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Physics

P-53
DOSIMETRIC EFFECTS OF PLASTIC APPLICATORS AND METALLIC SOURCE GUIDE TUBES IN 192Ir HDR TREATMENTS OF THE VAGINA: MONTE CARLO SIMULATIONS AND ION-CHAMBER MEASUREMENTS
Sung-Joon Ye, Ph.D.,1 Ivan A Brezovich, Ph.D.1 1Radiation Oncology, University of Alabama School of Medicine, Birmingham, AL.
P-54
SKIN AND CONTRALATERAL BREAST SURFACE DOSE ASSOCIATED WITH MAMMOSITE HIGH DOSE RATE BREAST BRACHYTHERAPY
Ahmir Sadeghi, PhD,1 Bradley Prestidge, MD,2 Arthur Rosenthal, MD,3 Leticia Salinas, MS,1 Renee Lee, MS,1 James Hevezi, PhD,1 1Radiation Physics, Cancer Therapy & Research Center, San Antonio, TX; 2Radiation Oncology, Cancer Therapy & Research Center, San Antonio, TX; 3Surgery, SW Texas Methodist Hospital, San Antonio, TX.

P-55
AUTOMATED HDR OPTIMIZATION USING DIFFERENTIAL EVOLUTION
David A Silvern, DrPH,1 Marco Zaider, PhD,2 Gilad N Cohen, MS,2 Patricia J Harrington, BA,2 Nitin K Mathur, MS,2 Michael J Zelefsky, MD,3 1Oncology: Radiotherapy Unit, Rabin Medical Center: Beilinson Campus, Petah Tikva, Israel; 2Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY; 3Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York.

P-56
MODELING SEED MISPLACEMENT BY SIMULATING TISSUE DEFORMATIONS
Ron Alterovitz, B.S.,1 Jean Pouliot, Ph.D.,2 Richard Taschereau, Ph.D.,2 I-Chow Hsu, M.D.,2 Ken Goldberg, Ph.D.3 1Department of Industrial Engineering & Operations Research, University of California Berkeley, Berkeley, CA; 2Department of Radiation Oncology, University of California San Francisco, San Francisco, CA; 3Departments of IEOR and EECS, University of California Berkeley, Berkeley, CA.

P-57
2D VERSUS 3D PLANNING OF INTRACAVITARY HDR TREATMENTS FOR GYNECOLOGICAL TUMORS
Anil Sethi, Ph.D.,1 Kevin Albuquerque, M.D.,1 Leonid B Leybovich, Ph.D.,1 Noushin Izadifar, M.D.,1 Nesrin Dogan, Ph.D.,1 Glenn P Glasgow, Ph.D.1 1Radiation Oncology, Loyola University Medical Center, Maywood, IL.

P-58
HIGH DOSE RATE BRACHYTHERAPY AND EXTERNAL BEAM: LONG TERM RESULTS IN CANCER OF THE PROSTATE
D Jeffrey Demanes, M.D.,1 Rodney R Rodriguez, Ph.D., M.D.,1 Lionel Schour, M.D., M.S.,1 David Brandt, M.A.,1 Gillian A Altieri, C.M.D.,1 Ramina Ravanera,1 Robert Smith, M.D.1 1High Dose Rate Brachytherapy, California Endocurietherapy Cancer Center, Oakland, CA.

P-59
FEASIBILITY OF RADIOIMMUNOGUIDED PROSTATE BRACHYTHERAPY AS SALVAGE FOR LOCAL FAILURE FOLLOWING EXTERNAL BEAM RADIATION
Rodney J Ellis, MD,1 Amy Vertocnik, MS,2 Edward Y Kim, MD,2 Hang Zhou, MD,2 D B Sodee, MD,3 J P Spirnak, MD,4 Kurt H Dinchman, MD,4 Valdir Colussi, PhD,2 Martin I Resnick, MD,5 1Radiation Oncology, Aultman Hospital, Canton, OH; 2Radiation Oncology, University Hospitals of Cleveland / CWRU, Cleveland, OH; 3Radiology, University Hospitals of Cleveland / CWRU, Cleveland, OH; 4Urology, Metrohealth Medical Center, Cleveland, OH; 5Urology, University Hospitals of Cleveland / CWRU, Cleveland, OH.
P-60
LOCALIZATION OF NEUROVASCULAR BUNDLES ON PELVIC CT AND EVALUATION OF RADIATION DOSE TO STRUCTURES PUTATIVELY INVOLVED IN ERECTILE DYSFUNCTION AFTER PROSTATE BRACHYTHERAPY
Jean F Lundberg,1 Jeffrey H Newhouse, M.D.,2 Ronald D Ennis, M.D.1 1Radiation Oncology; 2Radiology, Columbia Univ, New York, NY.

P-61
SWELLING POST IMPLANT IS IN PART AN ARTIFACT OF IMAGING MODALITY
Patrick McLaughlin, MD, Vrinda Narayana, PhD, Sara Troyer, BS, Joseph Herman, MD, Peter Roberson, pHD. 1Radiation Oncology, University of Michigan, Ann Arbor, MI; 2Radiation Oncology, Providence Hospital, Southfield, MI.

P-62
HIGH DOSE RATE (HDR) MONOTHERAPY FOR EARLY STAGE PROSTATE CANCER: PRELIMINARY RESULTS
Rodney R Rodriguez, Ph.D., M.D.,1 D Jeffrey Demanes, M.D.,1 Gillian A Altieri, C.M.D.,1 Lionel Schour, M.D.,1 David Brandt, M.A.,1 Ramina Ravanera,1 Robert Smith, M.D.1 1High Dose Rate Brachytherapy, California Endocurietherapy Cancer Center, Oakland, CA.

P-63
FACTORS ASSOCIATED WITH THE NEED FOR SELF-INTERMITTENT CATHETERIZATION AFTER PROSTATE BRACHYTHERAPY
David J Schwartz, MD,1 Steven E Schild, MD,1 William W Wong, MD,1 Sujay Vora, MD.1 1Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ.

P-64
DOSIMETRIC PREDICTORS OF PROLONGED GRADE 2 URINARY SYMPTOMS AFTER PROSTATE IMPLANTATION: WHAT DOES THE URETHRAL DVH TEACH US?
Michael J Zelefsky, M.D.,1 Yoshiya Yamada, M.D.,1 Gilad Cohen, M.S.,1 Leah Ben-Porat, B.A,1 Marco Zaider, Ph.D.1 1Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.

P-65
OFFICE-BASED CT-ULTRASOUND INTERACTIVE TRANSPERINEAL PROSTATE BRACHYTHERAPY: A REAL-TIME DOSIMETRY ANALYSIS AND QUALITY IMPROVEMENT METHOD REPORT OF 14 CASES
Donald B Fuller, MD,1 Haoran Jin, PhD,1 Tahir Ijaz, MD,1 Marie D Silverman, CMD,1 Steve J Hardy, CMD,1 James A Koziol, PhD,2 Anne C Feng.2 1Radiotherapy, Radiation Medical Group, San Diego, CA; 2Statistics, Scripps Cancer Center, La Jolla, CA.

P-66
PROSTATE BRACHYTHERAPY USING CONSCIOUS SEDATION AND LOCAL ANESTHESIA: PATIENT SATISFACTION SURVEY, SHORT-TERM MORBIDITY ASSESSMENT AND IMPLANT QUALITY ASSESSMENT
Donald B Fuller, MD, Mary Kay Gorman, RN, Carol Holcomb, RN, Tahir Ijaz, MD. 1Radiotherapy, Radiation Medical Group, San Diego, CA.
P-67
EPIDIDYMITIS FOLLOWING PROSTATE BRACHYTHERAPY
S Christopher Hoffelt, MD, Kent Wallner, MD, Greg Merrick, MD. 1 Radiation Oncology, Oregon Health Sciences University, Portland, OR; 2Radiation Oncology, Puget Sound Health Care System, Dept of Veterans Affairs, U. of Washington, Seattle, WA; 3Radiation Oncology, Schiffler Cancer Center, Wheeling, WV.

P-68
A PHASE I/II STUDY FOR THE TREATMENT OF PATIENTS WITH RECURRENT, NONMETASTATIC PROSTATE CANCER: A NEW TREATMENT OPTION
Robert A Ivker, D.O., 1 Allison Sacher, M.D., 1 Alan Helfman, M.D., 1 Stuart Shoengold, M.D., 1 Alan Strumeyer, M.D., 1 Loren Bell, C.M., 1 Will Chen, PH.D., 1 Lawrence R Coia, M.D. 2 1Radiation Oncology, Newark Beth Israel Medical Center, Newark, NJ; 2Radiation Oncology, Community Medical Center, Toms River, NJ.

P-69
PROSTATE CANCER WITH LARGE GLANDS TREATED WITH THREE DIMENSIONAL COMPUTED TOMOGRAPHY-GUIDED PARARECTAL BRACHYTHERAPY, UP TO EIGHT YEARS FOLLOW-UP
Panos G Koutrouvelis, M.D., Niko Lailas, M.D., Stuart Katz, M.D., James Sehn, M.D., Guillermo Gil-Montero, M.D., Nabil Khawand, M.D. 1Uro-Radiology Prostate Institute, Vienna, VA.

P-70
ACUTE URINARY MORBIDITY FOLLOWING PROSTATE BRACHYTHERAPY: THE IMPACT OF INTRAOPERATIVE DOSIMETRY
Karen E Loeb-Borofsky, M.D., 1 Jamie A Cesaretti, M.D., 1 Nelson N Stone, M.D., 2 Richard G Stock, M.D. 1 1Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY; 2Department of Urology, Mount Sinai School of Medicine, New York, NY.

P-71
THE EFFECT OF HORMONAL MANIPULATION ON URINARY FUNCTION FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY
Gregory S Merrick, M.D., 1,3 Wayne M Butler, PhD, 1,3 Kent E Wallner, MD, 2 Brian C Murray, BS, 1 Zachariah A Allen, MS, 1 Jonathan H Lief, PhD, 1,3 Robert W Galbreath, PhD, 1,3 Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV; 2Department of Veterans Affairs, Puget Sound Health Care System, Seattle, WA; 3Wheeling Jesuit University, Wheeling, WV.

P-72
HORMONAL THERAPY, BRACHYTHERAPY, AND EXTERNAL BEAM IRRADIATION IN THE TREATMENT OF HIGH RISK PROSTATE CANCER: POST-TREATMENT BIOPSY AND PSA OUTCOMES
Oren Cahlon, B.S., 1 Richard G Stock, M.D., 1 Marisa A Kollmeier, M.D., 1 Nelson N Stone, M.D. 2 1Department of Radiation Oncology, Mount Sinai School of Medicine, Mount Sinai Medical Center, New York, NY; 2Department of Urology, Mount Sinai School of Medicine, Mount Sinai Medical Center, New York, NY.

P-74
A TURP DEFECT DOES NOT COMPROMISE PROSTATE IMPLANT DOSIMETRY
Jamie A Cesaretti, MD, 1 Richard G Stock, MD, 1 Nelson N Stone, MD, 2 Marisa A Kollmeier, MD. 1 1Radiation Oncology, Mount Sinai School of Medicine, New York, NY; 2Urology, Mount Sinai School of Medicine, New York, NY.
P-77
ASSESSMENT OF RADIATION SAFETY INSTRUCTIONS TO PATIENTS BASED ON MEASURED DOSE RATES FOLLOWING PROSTATE BRACHYTHERAPY
Lawrence T Dauer, MS,1 Michael J Zelefsky, MD,2 Christopher L. Horan,1 Yoshiya Yamada, MD,2 Jean M St. Germain, MS.1
1Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY; 2Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.

P-78
ULTRASOUND VIBRO-ACOUSTOGRAPHY (UVA) FOR PERMANENT PROSTATE BRACHYTHERAPY: MOVING TOWARDS REAL-TIME INTRAOPERATIVE DOSIMETRY
Brian J Davis, MD PhD,1 Randall R. Kinnick,2 Mostafa Fatemi, PhD,2 Garrett H. Lischer, MD,1 James F Greenleaf, PhD.2
1Radiation Oncology, Mayo Clinic and Foundation, Rochester, MN; 2Physiology and Biophysics, Basic Ultrasound Research Laboratory, Mayo Clinic and Foundation, Rochester, MN.

P-79
COMBINATION CONFORMAL RADIOTHERAPY AND RADIOIMMUNOGUIDED TRANSPERINEAL Pd-103 IMPLANTATION FOR PATIENTS WITH INTERMEDIATE AND UNFAVORABLE RISK PROSTATE ADENOCARCINOMA
Rodney J Ellis, MD,1 Edward Y Kim, MD,2 Amy Vertocnik, MS,2 Bruce Sodee, MD,3 Hang Zhou, MD,2 Ben Young, BS,2 Pingfu Fu, PhD,3 John P Spirnak, MD,4 Valdir Colussi, PhD,2 Martin I Resnick, MD.5 1Radiation Oncology, Aultman Hospital, Canton, OH; 2Radiation Oncology, University Hospitals of Cleveland / CWRU, Cleveland, OH; 3Radiology, University Hospitals of Cleveland / CWRU, Cleveland, OH; 4Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH; 5Urology, University Hospitals of Cleveland / CWRU, Cleveland, OH.

Soft Tissue Sarcoma

P-80
OUTCOME OF COMBINED BRACHYTHERAPY AND EXTERNAL BEAM RADIATION THERAPY IN PRIMARY HIGH-GRADE SOFT TISSUE SARCOMA OF THE EXTREMITY
James E Lee, M.D.,1 Kaled M Alektiar, M.D.,1 Jordan M Jacobs, B.S.,1 Michael J Zelefsky, M.D.,1 Murray F Brennan, M.D.2
1Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY; 2Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
General Evaluation

Many of the comments and ideas received at previous meetings were considered when designing this program. Your opinions and reactions are important and will be actively considered for future meetings.

*Please return your completed evaluation to the Registration desk*

Program Objectives

- To ensure a comprehensive understanding of the expanding role of imaging within the practice of brachytherapy. This will be accomplished through the exploration of advances in treatment technique and dosimetric evaluation as well as treatment outcome in gynecologic, breast, prostate and endovascular brachytherapy.

- To increase the understanding of all aspects of brachytherapy application, including indications for use, technical considerations, quality assurance programs and outcome evaluations.

Thursday, May 8

Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

**Alektiar/Small** — Overall rating of presentation (please circle one)  

5 4 3 2 1

*Endometrial Cancer: Indications, Techniques, and Results*

Were objectives stated at beginning of presentation?  ☐ Yes ☐ No

Were objectives met?  ☐ Yes ☐ No

Was presentation clear and concise?  ☐ Yes ☐ No

Will this presentation enhance your practice?  ☐ Yes ☐ No

If yes, please rate how important this “enhancement” will be  

☐ very ☐ moderately ☐ somewhat ☐ not very

General Comments:
Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

Gynecologic Brachytherapy: Chair, Beth Erickson

**Mayr** — Overall rating of presentation (please circle one) 5 4 3 2 1

*Imaging for Gynecologic Malignancies*

- Were objectives stated at beginning of presentation? □ Yes □ No
- Were objectives met? □ Yes □ No
- Was presentation clear and concise? □ Yes □ No
- Will this presentation enhance your practice? □ Yes □ No

If yes, please rate how important this “enhancement” will be

□ very □ moderately □ somewhat □ not very

General Comments:

**Williamson** — Overall rating of presentation (please circle one) 5 4 3 2 1

*Image-Guided Brachytherapy-Efficacy and Limitations*

- Were objectives stated at beginning of presentation? □ Yes □ No
- Were objectives met? □ Yes □ No
- Was presentation clear and concise? □ Yes □ No
- Will this presentation enhance your practice? □ Yes □ No

If yes, please rate how important this “enhancement” will be

□ very □ moderately □ somewhat □ not very

General Comments:

**Poetter** — Overall rating of presentation (please circle one) 5 4 3 2 1

*MRI-based Brachytherapy for Cervical Carcinoma*

- Were objectives stated at beginning of presentation? □ Yes □ No
- Were objectives met? □ Yes □ No
- Was presentation clear and concise? □ Yes □ No
- Will this presentation enhance your practice? □ Yes □ No

If yes, please rate how important this “enhancement” will be

□ very □ moderately □ somewhat □ not very

General Comments:

Responses to this questionnaire are *Proprietary* to the ACR and the ABS
Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

Chadha — Overall rating of presentation (please circle one) 5 4 3 2 1

Proffered Papers

Were objectives stated at beginning of presentation?  □ Yes □ No
Were objectives met?  □ Yes □ No
Was presentation clear and concise?  □ Yes □ No
Will this presentation enhance your practice?  □ Yes □ No
If yes, please rate how important this “enhancement” will be
□ very □ moderately □ somewhat □ not very

General Comments:

Erickson — Overall rating of presentation (please circle one) 5 4 3 2 1

ABS Presidential Address

Were objectives stated at beginning of presentation?  □ Yes □ No
Were objectives met?  □ Yes □ No
Was presentation clear and concise?  □ Yes □ No
Will this presentation enhance your practice?  □ Yes □ No
If yes, please rate how important this “enhancement” will be
□ very □ moderately □ somewhat □ not very

General Comments:

Harrison — Overall rating of presentation (please circle one) 5 4 3 2 1

Henschke Lecture

Were objectives stated at beginning of presentation?  □ Yes □ No
Were objectives met?  □ Yes □ No
Was presentation clear and concise?  □ Yes □ No
Will this presentation enhance your practice?  □ Yes □ No
If yes, please rate how important this “enhancement” will be
□ very □ moderately □ somewhat □ not very

General Comments:

Responses to this questionnaire are Proprietary to the ACR and the ABS
Breast Brachytherapy: Chair, Douglas Arthur

Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

Arthur — Overall rating of presentation (please circle one)  5 4 3 2 1

APBI Scientific/Investigational Update

Were objectives stated at beginning of presentation? □ Yes □ No
Were objectives met? □ Yes □ No
Was presentation clear and concise? □ Yes □ No
Will this presentation enhance your practice? □ Yes □ No
If yes, please rate how important this “enhancement” will be
□ very □ moderately □ somewhat □ not very

General Comments:

Kuske — Overall rating of presentation (please circle one)  5 4 3 2 1

RTOG Phase II Trial Update

Were objectives stated at beginning of presentation? □ Yes □ No
Were objectives met? □ Yes □ No
Was presentation clear and concise? □ Yes □ No
Will this presentation enhance your practice? □ Yes □ No
If yes, please rate how important this “enhancement” will be
□ very □ moderately □ somewhat □ not very

General Comments:

Polgar — Overall rating of presentation (please circle one)  5 4 3 2 1

Hungarian Trial Phase II/III Update

Were objectives stated at beginning of presentation? □ Yes □ No
Were objectives met? □ Yes □ No
Was presentation clear and concise? □ Yes □ No
Will this presentation enhance your practice? □ Yes □ No
If yes, please rate how important this “enhancement” will be
□ very □ moderately □ somewhat □ not very

General Comments:

Responses to this questionnaire are Proprietary to the ACR and the ABS
Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

**Wazer** — Overall rating of presentation (please circle one)  5  4  3  2  1

*Observations on Toxicity*

Were objectives stated at beginning of presentation?  ☐ Yes  ☐ No
Were objectives met?  ☐ Yes  ☐ No
Was presentation clear and concise?  ☐ Yes  ☐ No
Will this presentation enhance your practice?  ☐ Yes  ☐ No
If yes, please rate how important this “enhancement” will be
  ☐ very  ☐ moderately  ☐ somewhat  ☐ not very

General Comments:

---

**Keisch, Donath** — Overall rating of presentation (please circle one)  5  4  3  2  1

*Propferred Papers*

Were objectives stated at beginning of presentation?  ☐ Yes  ☐ No
Were objectives met?  ☐ Yes  ☐ No
Was presentation clear and concise?  ☐ Yes  ☐ No
Will this presentation enhance your practice?  ☐ Yes  ☐ No
If yes, please rate how important this “enhancement” will be
  ☐ very  ☐ moderately  ☐ somewhat  ☐ not very

General Comments:

---

**Annual Debate I**

**Wazer, Vicini, Recht** — Overall rating of presentation (please circle one)  5  4  3  2  1

*Accelerated Partial Breast Irradiation is Equivalent to Standard Whole Breast Irradiation*

Were objectives stated at beginning of presentation?  ☐ Yes  ☐ No
Were objectives met?  ☐ Yes  ☐ No
Was presentation clear and concise?  ☐ Yes  ☐ No
Will this presentation enhance your practice?  ☐ Yes  ☐ No
If yes, please rate how important this “enhancement” will be
  ☐ very  ☐ moderately  ☐ somewhat  ☐ not very

General Comments:

---

Responses to this questionnaire are *Proprietary* to the ACR and the ABS
Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

**Friday, May 9**

Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

**Refresher Course**

**Arthur** — Overall rating of presentation (please circle one) 5 4 3 2 1

*Essentials of Breast Brachytherapy – Multi-Cath and Mammosite*

Were objectives stated at beginning of presentation? □ Yes □ No
Were objectives met? □ Yes □ No
Was presentation clear and concise? □ Yes □ No
Will this presentation enhance your practice? □ Yes □ No
If yes, please rate how important this “enhancement” will be

□ very □ moderately □ somewhat □ not very

General Comments:

---

**Vascular Brachytherapy, Chair, Phillip Devlin**

**Harrison** — Overall rating of presentation (please circle one) 5 4 3 2 1

*Dosimetry for Vascular Brachytherapy*

Were objectives stated at beginning of presentation? □ Yes □ No
Were objectives met? □ Yes □ No
Was presentation clear and concise? □ Yes □ No
Will this presentation enhance your practice? □ Yes □ No
If yes, please rate how important this “enhancement” will be

□ very □ moderately □ somewhat □ not very

General Comments:
Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

**Cormack** — Overall rating of presentation (please circle one)  
5  4  3  2  1  
*Evaluation of Overlap and Geographic Miss Associated with Manual Pullback Procedure for IVBT*

- Were objectives stated at beginning of presentation? [ ] Yes [ ] No
- Were objectives met? [ ] Yes [ ] No
- Was presentation clear and concise? [ ] Yes [ ] No
- Will this presentation enhance your practice? [ ] Yes [ ] No

If yes, please rate how important this “enhancement” will be
- [ ] very
- [ ] moderately
- [ ] somewhat
- [ ] not very

**Mignano** — Overall rating of presentation (please circle one)  
5  4  3  2  1  
*Intravascular Brachytherapy Using [Sup]90[Sr] for Saphenous Vein Grafts Having Diameters Ranging from 2.0-5.0mm*

- Were objectives stated at beginning of presentation? [ ] Yes [ ] No
- Were objectives met? [ ] Yes [ ] No
- Was presentation clear and concise? [ ] Yes [ ] No
- Will this presentation enhance your practice? [ ] Yes [ ] No

If yes, please rate how important this “enhancement” will be
- [ ] very
- [ ] moderately
- [ ] somewhat
- [ ] not very

**Devlin** — Overall rating of presentation (please circle one)  
5  4  3  2  1  
*Coronary Brachytherapy in the Era of Drug Eluting Stents*

- Were objectives stated at beginning of presentation? [ ] Yes [ ] No
- Were objectives met? [ ] Yes [ ] No
- Was presentation clear and concise? [ ] Yes [ ] No
- Will this presentation enhance your practice? [ ] Yes [ ] No

If yes, please rate how important this “enhancement” will be
- [ ] very
- [ ] moderately
- [ ] somewhat
- [ ] not very

**General Comments:**
Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

**Abner** — Overall rating of presentation (please circle one)  

<table>
<thead>
<tr>
<th></th>
<th>5</th>
<th>4</th>
<th>3</th>
<th>2</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall rating of presentation</td>
<td>☐ Yes</td>
<td>☐ No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

_Treatment Of Refractory In-Stent Restenosis with Intravascular Brachytherapy And Paclitaxel Coated Stents: Determination Of Efficacy Of Radiosensitization Using Finite Element Methods To Model Drug Uptake_

Were objectives stated at beginning of presentation? ☐ Yes ☐ No  
Were objectives met? ☐ Yes ☐ No  
Was presentation clear and concise? ☐ Yes ☐ No  
Will this presentation enhance your practice? ☐ Yes ☐ No  
If yes, please rate how important this “enhancement” will be  
☐ very ☐ moderately ☐ somewhat ☐ not very

General Comments:

**Tripuraneni** — Overall rating of presentation (please circle one)  

<table>
<thead>
<tr>
<th></th>
<th>5</th>
<th>4</th>
<th>3</th>
<th>2</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall rating of presentation</td>
<td>☐ Yes</td>
<td>☐ No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

_Vascular Brachytherapy for Peripheral Disease – An Update_

Were objectives stated at beginning of presentation? ☐ Yes ☐ No  
Were objectives met? ☐ Yes ☐ No  
Was presentation clear and concise? ☐ Yes ☐ No  
Will this presentation enhance your practice? ☐ Yes ☐ No  
If yes, please rate how important this “enhancement” will be  
☐ very ☐ moderately ☐ somewhat ☐ not very

General Comments:

**Orton** — Overall rating of presentation (please circle one)  

<table>
<thead>
<tr>
<th></th>
<th>5</th>
<th>4</th>
<th>3</th>
<th>2</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall rating of presentation</td>
<td>☐ Yes</td>
<td>☐ No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

_Proffered Papers_

Were objectives stated at beginning of presentation? ☐ Yes ☐ No  
Were objectives met? ☐ Yes ☐ No  
Was presentation clear and concise? ☐ Yes ☐ No  
Will this presentation enhance your practice? ☐ Yes ☐ No  
If yes, please rate how important this “enhancement” will be  
☐ very ☐ moderately ☐ somewhat ☐ not very

General Comments:

Responses to this questionnaire are _Proprietary_ to the ACR and the ABS
Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

Aronowicz — Overall rating of presentation (please circle one)  5  4  3  2  1

History

Were objectives stated at beginning of presentation? □ Yes □ No
Were objectives met? □ Yes □ No
Was presentation clear and concise? □ Yes □ No
Will this presentation enhance your practice? □ Yes □ No
If yes, please rate how important this “enhancement” will be
□ very □ moderately □ somewhat □ not very

General Comments:

Prostate Brachytherapy, Chair, W. Robert Lee

Lee, Zelefsky — Overall rating of presentation (please circle one)  5  4  3  2  1

Contouring Consensus Results

Were objectives stated at beginning of presentation? □ Yes □ No
Were objectives met? □ Yes □ No
Was presentation clear and concise? □ Yes □ No
Will this presentation enhance your practice? □ Yes □ No
If yes, please rate how important this “enhancement” will be
□ very □ moderately □ somewhat □ not very

General Comments:

Lee, Manning — Overall rating of presentation (please circle one)  5  4  3  2  1

Proffered Papers

Were objectives stated at beginning of presentation? □ Yes □ No
Were objectives met? □ Yes □ No
Was presentation clear and concise? □ Yes □ No
Will this presentation enhance your practice? □ Yes □ No
If yes, please rate how important this “enhancement” will be
□ very □ moderately □ somewhat □ not very

General Comments:

Responses to this questionnaire are Proprietary to the ACR and the ABS
Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

**Beyer, Prestidge, Hagan** — Overall rating of presentation (please circle one)  5 4 3 2 1

*Salvage Brachytherapy – Imaging, Technique and Results*

Were objectives stated at beginning of presentation? ☐ Yes ☐ No
Were objectives met? ☐ Yes ☐ No
Was presentation clear and concise? ☐ Yes ☐ No
Will this presentation enhance your practice? ☐ Yes ☐ No
If yes, please rate how important this “enhancement” will be ☐ very ☐ moderately ☐ somewhat ☐ not very

General Comments:

---

**Saturday, May 10**

**Refresher Course**

**Sylvester** — Overall rating of presentation (please circle one)  5 4 3 2 1

*Prostate Brachytherapy*

Were objectives stated at beginning of presentation? ☐ Yes ☐ No
Were objectives met? ☐ Yes ☐ No
Was presentation clear and concise? ☐ Yes ☐ No
Will this presentation enhance your practice? ☐ Yes ☐ No
If yes, please rate how important this “enhancement” will be ☐ very ☐ moderately ☐ somewhat ☐ not very

General Comments:

---

**Stock, Potters** — Overall rating of presentation (please circle one)  5 4 3 2 1

*Proffered Papers*

Were objectives stated at beginning of presentation? ☐ Yes ☐ No
Were objectives met? ☐ Yes ☐ No
Was presentation clear and concise? ☐ Yes ☐ No
Will this presentation enhance your practice? ☐ Yes ☐ No
If yes, please rate how important this “enhancement” will be ☐ very ☐ moderately ☐ somewhat ☐ not very

General Comments:

Responses to this questionnaire are Proprietary to the ACR and the ABS
Please circle the appropriate rating number, with 5 as the highest score and 1 as the lowest and check “yes” or “no”

D’Amico, Davis, McLaughlin — Overall rating of presentation (please circle one)  5 4 3 2 1
Advances in Prostate Brachytherapy

Were objectives stated at beginning of presentation?  Yes  No
Were objectives met?  Yes  No
Was presentation clear and concise?  Yes  No
Will this presentation enhance your practice?  Yes  No
If yes, please rate how important this “enhancement” will be
- very
- moderately
- somewhat
- not very

General Comments:

Annual Debate II

Lee, Merrick, Crook — Overall rating of presentation (please circle one)  5 4 3 2 1
“CT Scan Evaluation is Adequate for Post Implant Quality Assessment”

Were objectives stated at beginning of presentation?  Yes  No
Were objectives met?  Yes  No
Was presentation clear and concise?  Yes  No
Will this presentation enhance your practice?  Yes  No
If yes, please rate how important this “enhancement” will be
- very
- moderately
- somewhat
- not very

General Comments:

Responses to this questionnaire are Proprietary to the ACR and the ABS
**General Questions**

<table>
<thead>
<tr>
<th>The overall conference was</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
</table>

What influenced you to attend this meeting?
- Program
- Date
- Location
- CME credit

**Program**

<table>
<thead>
<tr>
<th>Would you recommend this program to your peers?</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Were course materials adequate for this program?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>The meeting allowed enough time for question and answers</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>The overall program met my expectations</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Did you perceive any portion of this program to be commercially biased, i.e., did you at any time think a presenter was “selling” a product or company?
- Yes
- No

If “yes” please explain: __________________________________________________________

 Comments/Suggestions: __________________________________________________________

**Facility**

<table>
<thead>
<tr>
<th>Was audiovisual service adequate</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Was the hotel/facility adequate for this meeting?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Would you attend a meeting at this hotel/facility again</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Comments/Suggestions: __________________________________________________________

Suggestions for Future Topics: ____________________________________________________

*Thank you for taking time to complete this evaluation.*

Responses to this questionnaire are Proprietary to the ACR and the ABS
ABS Questionnaire: May, 2003

What issues or projects would you like to see the ABS pursue in the next year (research projects, regulatory issues, annual meeting topics, Brachytherapy School topics, guidelines, standards, cooperative efforts with other societies etc)?

1. __________________________________________________________________________________________________

2. __________________________________________________________________________________________________

3. __________________________________________________________________________________________________

4. __________________________________________________________________________________________________

5. __________________________________________________________________________________________________

Are there any committees you would like to serve on? Please check the boxes of the committees you are interested in.

- Professional and Public Relations
  - Government Relations
  - Socioeconomics
  - Public Relations (website and newsletter)
  - Liaison

- Standing Committees
  - Finance (including corporate support)
  - Bylaws
  - Nominating
  - Membership
  - Awards

- Clinical Research/Practice
  - Research
  - Guidelines
  - Physics

- Education
  - Annual Meeting
  - Brachytherapy
  - Education (CME portion of website)

Name ______________________________________________________________________________________________

Phone Number ______________________________ Fax Number ______________________________

E-mail address ______________________________________________________________________________________

Mailing address _______________________________________________________________________________________

___________________________________________________________________________________________________________

Please return to the ABS Registration Desk or fax to 703-435-4390 after the Annual Meeting.
2004 International Meeting: ABS & GEC-ESTRO

May 13-15
World Trade Center (WTCB)
Barcelona, Spain

Every four years the ABS supports the international meeting of the GEC-ESTRO organization. We hope that you can join us in Barcelona next spring – for more information and future updates, please visit the web site www.estro.be
American Brachytherapy Society
The Waldorf-Astoria  ▶ May 8–10, 2003
Floor Plans

Waldorf–Astoria Hotel  ▶ Lobby Level

Waldorf–Astoria Hotel  ▶ Third Floor

Waldorf–Astoria Hotel  ▶ Fourth Floor

Waldorf–Astoria Hotel  ▶ Eighteenth Floor

1. Park Avenue Suite North
2. Park Avenue Suite Center
3. Park Avenue Suite North
4. Vanderbilt Suite
5. Duke of Windsor Suite
6. Conrad Suite Salon
7. Conrad Suite Foyer
8. Conrad Suite Dining Room
9. Herbert Hoover Suite Dining Room
10. Herbert Hoover Suite Foyer
11. Herbert Hoover Suite Salon
12. Marilyn’s Suite
13. Vertes Suite “U”
14. Vertes Suite “V”
15. Louis XVI Suite West
16. Louis XVI Suite Center
17. Louis XVI Suite East
18. Cole Porter Suite A
19. Cole Porter Suite B
20. The Starlight Roof - North Terrace
21. The Starlight Roof - Center
22. The Starlight Roof - South Terrace
23. North Foyer
24. South Foyer
25. Rotunda
26. Towers Elevators
27. West Elevators
28. Palm Room
29. Gramercy Suite
30. Metropolitan Suite West
31. Metropolitan Suite East
32. Jansen Suite
33. Carnegie Suite
34. Morgan Suite
35. Maxwell Suite
36. Norse Suite
37. Sutton Suite
38. The Library
39. New Amsterdam Suite
40. Lexington Suite
41. Beekman Suite

Waldorf–Astoria Hotel  ▶ Lobby Level

- TERRACE COURT
- HI PPO WLD.
- HI PPO WLD.
- GRAND BALLROOM
- EMPIRE ROOM

Waldorf–Astoria Hotel  ▶ Third Floor

- Basil Room
- Jade Room
- Silver Corridor
- John Jacob Astor Salon
- West Foyer
- Main Floor
- East Foyer

Waldorf–Astoria Hotel  ▶ Fourth Floor

Waldorf–Astoria Hotel  ▶ Eighteenth Floor